Why the study?
What are the potential beneficial and harmful interactions between drugs and implantable cardioverter defibrillators?
What are the potential beneficial and harmful interactions between drugs and implantable cardioverter defibrillators?
Clinicians and pharmacists must be aware of potential drug-device interactions in patients with ICDs, as medications can significantly alter defibrillation thresholds and device function.
Supports clinician awareness of drug-ICD interactions; leaves open the need for prospective trials to guide management.
We reviewed the interactions of drugs and defibrillators, with emphasis on implantable cardioverter defibrillators. Articles were identified by searching MEDLINE from 1966 to the present; additional sources were identified from reference lists in these articles. Drugs have the potential for both beneficial and harmful interactions with electrical therapy. Beneficial interactions include reductions in the energy required to defibrillate the heart and in the occurrence of arrhythmia resulting in decreased shock frequency, prolonged device longevity, and improved patient comfort. Potentially harmful interactions include altering the detection of ventricular tachycardia; altering the pacing threshold, resulting in interference with bradycardia or antitachycardia pacing; development of incessant ventricular tachycardia; and increasing the energy required to defibrillate the heart. As the use of implantable cardioverter defibrillators increases, pharmacists should be aware of the potential for drug-device interactions.
No takes yet. Share an insight, caveat, or question.
Carnes et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: